Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to Dose First Patient in Phase 2 Postpartum Depression Study in 2H 2023 President and CEO Presenting at Biotech Showcase in San Francisco on […]
- May 2023
The article Psilocybin Therapy is Now Legal in Oregon — But There’s a Catch was originally published on Microdose.
On January 1st, Oregon became the first state in the USA to legalize psilocybin therapy. From here on, adults 21 years of age and older will be able to receive psilocybin-assisted therapy, conducted by a licensed organization. The only catch? As of yet, there are no licensed groups that can legally provide the therapy. This […]
The article MAPS’ Positive Results Confirmed in Second Phase 3 Trial was originally published on Microdose.
MAPS has announced that the second part of its Phase 3 trial of MDMA-assisted therapy for PTSD has confirmed prior positive trial results. The first part of the Phase 3 trials had potentially historically significant results, and the entire industry has been waiting for the second part of its Phase 3 study. A successful outcome in […]
- TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C […]
- VANCOUVER, BC, Dec. 30, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced the distribution of a year-end letter from Chief Executive Officer, Benjamin Lightburn, which can be viewed on Filament’s website. The letter highlights key milestones achieved by […]
- Load more...